Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a hereditary neurodegenerative disorder for which biological indicators of disease progression, or disease stage, would be especially important for therapeutic trials. 24S-hydroxycholesterol (24OHC) is a brain-generated cholesterol metabolite which has been associated with neurodegeneration, and alterations of cholesterol metabolism in murine HD models and patients' tissues have been recently identified. On these grounds, and with the aim of identifying putative biomarkers in HD, we studied cholesterol metabolism through the analysis in vivo of plasma 24OHC and cholesterol in two independent cohorts of controls and patients of Italian and British origin. We analysed a total of 62 controls, 96 HD symptomatic patients at different disease stages (stage 1-3), and 33 HD gene-positive pre-manifest subjects [pre-manifest HD (pre-HD)]. Cholesterol and 24OHC plasma levels were comparable in both the British and Italian subjects, and were not influenced by fasting or post-meal status. Cholesterol levels did not show differences between controls, pre-HD subjects and HD patients. In contrast, the plasma levels of 24OHC were significantly higher in controls than in HD patients at all disease stages (P < 0.001). Interestingly, in pre-HD subjects plasma 24OHC concentrations were similar to those of controls, and thus significantly greater than those of HD patients at any disease stage (P < 0.001). As expected, significant differences in caudate volumes between stage 1-2 HD patients and pre-HD subjects, and pre-HD subjects and controls were found. The pre-HD cohort of subjects was heterogeneous as to 24OHC levels, since subjects closer to predicted development of motor signs of disease had lower 24OHC levels than those far from onset. Our data indicate that the brain-generated cholesterol metabolite 24OHC measured in plasma was significantly depleted in HD patients at any disease stage, and it could discriminate pre-manifest subjects from patients with overt motor disease. However, 24OHC levels failed to mark further disease progression in patients with manifest HD. Overall, we demonstrate that 24OHC levels parallel the large decrease in caudate volumes observed in gene-positive subjects from pre-manifest to HD stage 1, thus reflecting a critical phase characterized by neuronal loss. We conclude that that 24OHC levels complement MRI morphometry as a valuable tool to follow neurodegenerative changes in the early stages of Huntington disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095 · cited 1×
“…2004); (ii) most de novo biosynthesis happens during brain development, whereas de novo cholesterol biosynthesis in the adult brain is limited (Dietschy and Turley 2004); (iii) cholesterol homeostasis is essential for proper brain function (Pfriger, 2003), and a constant equilibrium between…”
BackgroundBrain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044
Lütjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Sidén, A., Diczfalusy, U., & Björkhem, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9799 · Cited by 682 · cited 1×
“…content in the brain (Lund et al., 2003); (v) in the human adult brain cholesterol turnover gives rise to a daily flux of about 7 mg of 24OHC from the brain into the circulation (Lütjohann et al., 1996), so that 24OHC levels in plasma are taken as an index of brain cholesterol elimination.”
BackgroundSelf-citationcDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain
Lund, E. G., Guileyardo, J. M., & Russell, D. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7238 · Cited by 668
Cholesterol homeostasis and function in neurons of the central nervous system
Pfrieger, F. W. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3018-7 · Cited by 453
Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., & Russell, D. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303415200 · Cited by 421
Rate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease
Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L., Strand, A., Tarditi, A., Woodman, B., Racchi, M., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3355-05.2005 · Cited by 298
Self-citation
Cited by
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationHuntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Self-citationMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
“In the above study, a correlation with the degree of caudate atrophy measured by morphometric MRI had been found in preclinical HD and stage I HD patients (334).”
BackgroundSelf-citationBeyond the brain: widespread pathology in Huntington's disease
van der Burg, J. M., Björkqvist, M., & Brundin, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70178-4 · Cited by 363
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis
Luthi-Carter, R., Taylor, D. M., Pallos, J., Lambert, E., Amore, A., Parker, A., Moffitt, H., Smith, D. L., Runne, H., Gokce, O., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002924107 · Cited by 336
Oxysterols and neurodegenerative diseases
Björkhem, I., Cedazo-Minguez, A., Leoni, V., & Meaney, S. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.02.001 · Cited by 271
Self-citationHuntington's disease: The current state of research with peripheral tissues
Sassone, J., Colciago, C., Cislaghi, G., Silani, V., & Ciammola, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.012 · Cited by 175
Valenza, M., Leoni, V., Karasinska, J. M., Petricca, L., Fan, J., Carroll, J., Pouladi, M. A., Fossale, E., Nguyen, H. P., Riess, O., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0917-10.2010 · Cited by 166
“Recent studies in HD cells, mice, and patients indicated that reduced brain cholesterol biosynthesis may be a relevant phenotype in the human pathology (Sipione et al., 2002; Valenza et al., 2005, 2007a,b; Leoni et al., 2008).”
BackgroundSelf-citationCholesterol metabolism in Huntington disease
Karasinska, J. M., & Hayden, M. R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.132 · Cited by 154
Valenza, M., Marullo, M., Di Paolo, E., Cesana, E., Zuccato, C., Biella, G., & Cattaneo, E. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.162 · Cited by 133
Self-citationCYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington’s disease
Kacher, R., Lamazière, A., Heck, N., Kappes, V., Mounier, C., Despres, G., Dembitskaya, Y., Perrin, E., Christaller, W., Sasidharan Nair, S., et al. (2019) · Brain · doi:10.1093/brain/awz174 · Cited by 119
Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia
Saba, J., Couselo, F. L., Bruno, J., Carniglia, L., Durand, D., Lasaga, M., & Caruso, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666211201094608 · Cited by 117
“The plasma of HD patients showed a gradual decrease in 24OHC levels, which correlated with HD progression [209-211].”
Valenza, M., Chen, J. Y., Di Paolo, E., Ruozi, B., Belletti, D., Ferrari Bardile, C., Leoni, V., Caccia, C., Brilli, E., Di Donato, S., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505413 · Cited by 112
Self-citationEvidence for altered cholesterol metabolism in Huntington's disease post mortem brain tissue
Kreilaus, F., Spiro, A. S., McLean, C. A., Garner, B., & Jenner, A. M. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12286 · Cited by 92
Can Cholesterol Metabolism Modulation Affect Brain Function and Behavior?
Cartocci, V., Servadio, M., Trezza, V., & Pallottini, V. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25488 · Cited by 77
“Cholesterol metabolites seem to be reduced in manifest HD (Leoni et al., 2008, 2011) even though researches evaluating cholesterolemia have shown both low (Markianos et al., 2008; Wang et al., 2014) and normal levels (Leoni et al., 2008; Nambron et al., 2016) in HD patients compared to healthy…”
BackgroundResultSegatto, M., Leboffe, L., Trapani, L., & Pallottini, V. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140303142902 · Cited by 65
“The reduction in 24(S)-hydroxycholetserol plasma content is correlated with a decrease in the volume of HD caudatesamples [96], suggesting that the disruption in cholesterol homeostasis could contribute to the onset of HD pathology.”
BackgroundShankaran, M., Di Paolo, E., Leoni, V., Caccia, C., Ferrari Bardile, C., Mohammed, H., Di Donato, S., Kwak, S., Marchionini, D., Turner, S., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.11.013 · Cited by 54
Self-citationBirolini, G., Valenza, M., Di Paolo, E., Vezzoli, E., Talpo, F., Maniezzi, C., Caccia, C., Leoni, V., Taroni, F., Bocchi, V. D., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012519 · Cited by 27
Self-citationCholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets
Wang, N.-Q., Sun, P.-X., Shen, Q.-Q., & Deng, M.-Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04672-w · Cited by 19
“Moreover, changes in the cholesterol biosynthesis pathway and metabolic products have been noted in the brains of HD patients [21, 22], suggesting an imbalance in cholesterol homeostasis in HD.”
Lütjohann, D., Lopez, A. M., Chuang, J., Kerksiek, A., & Turley, S. D. (2018) · Lipids · doi:10.1002/lipd.12041 · Cited by 11
Metadata
- Authors
- Leoni, V., Mariotti, C., Tabrizi, S. J., Valenza, M., Wild, E. J., Henley, S. M. D., Hobbs, N. Z., Mandelli, M. L., Grisoli, M., Björkhem, I., Cattaneo, E., & Di Donato, S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-04
- Volume
- 131
- Issue
- 11
- Pages
- 2851-2859
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2136140769
- Cited by
- 145
- References
- 9
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.